Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06908304

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC

Sponsor: Maia Biotechnology

Conditions Carcinoma, Non-Small -Cell Lung

Interventions 6-Thio-2'-Deoxyguanosine Cemiplimab Docetaxel Gemcitabine alone Vinorelbine

Updated 3 times since 2025 Last updated: Jan 8, 2026 Started: Dec 8, 2025 Primary completion: Jul 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Carcinoma, Non-Small -Cell Lung and is currently actively recruiting participants. Maia Biotechnology leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE3
May 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maia Biotechnology

Data source: Maia Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Changhua, Taiwan , Chiayi City, Taiwan , Craiova, Romania , Istanbul, Turkey (Türkiye) , Kaohsiung City, Taiwan , Poznan, Poland , Taichung, Taiwan , Taipei, Taiwan and 2 more locations